Efficacy of Probiotic Therapy on Disease Outcomes in HLA-B27 Associated Anterior Uveitis

Hyderabad Eye Research Foundation0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Ability to give informed consent for participation.
•2.Males or females greater than or equal to 18 years of age.
•3.Patients and controls should not have received antibiotics, pro- or prebiotic treatment for at least three months prior to sample collection.
•4.Patients with Non-granulomatous anterior uveitis.
•5.Presenting AC reaction greater than or equal to grade 2.
•6.Onset less than or equal to 2 weeks.
•7.HLA-B27 positive
•8.All cohorts are matched for diet, age, gender, ethnicity etc.
•9.Rule out infectious etiology

•1.Posterior segment inflammation more than spillover vitritis.
•2.Active infectious uveitis
•3.Lens induced uveitis
•4.Non-HLA-B27 associated uveitis
•5.Any significant systemic or ocular disease that could compromise the uveitis in the study eye. These include, but are not limited to:
•a.Diabetic retinopathy: proliferative diabetic retinopathy (PDR) or non-proliferative diabetic retinopathy (NPDR).
•b.Wet age-related macular degeneration.
•c.Myopic degeneration with active sub-foveal choroidal neovascularization.
•d.Uncontrolled glaucoma, intraocular pressure of > 21 mm Hg while on medical therapy, or chronic hypotony ( <6 mm Hg).
•6.Any implantable corticosteroid-eluting device (e.g. Ozurdex, I-vation, triamcinolone acetonide [TA] intravitreal implant) in the study eye within the past 90 days.
•7.Any of the following treatments within 90 days prior to enrollments:
•a.Intravitreal injections (including steroids and anti-vascular endothelial growth factors);
•b.Posterior subtenon steroids.
•8.Free from antibiotic and systemic immunosuppressant use (three months prior to presentation and during the course of study).

发起方